Pathomechanisms of behavioral abnormalities in Huntington disease: an update
- PMID: 38874766
- DOI: 10.1007/s00702-024-02794-y
Pathomechanisms of behavioral abnormalities in Huntington disease: an update
Abstract
Huntington disease (HD), a devastating autosomal-dominant neurodegenerative disease caused by an expanded CAG trinucleotide repeat, is clinically characterized by a triad of symptoms including involuntary motions, behavior problems and cognitive deficits. Behavioral symptoms with anxiety, irritability, obsessive-compulsive behaviors, apathy and other neuropsychiatric symptoms, occurring in over 50% of HD patients are important features of this disease and contribute to impairment of quality of life, but their pathophysiology is poorly understood. Behavior problems, more frequent than depression, can be manifest before obvious motor symptoms and occur across all HD stages, usually correlated with duration of illness. While specific neuropathological data are missing, the relations between gene expression and behavior have been elucidated in transgenic models of HD. Disruption of interneuronal communications, with involvement of prefronto-striato-thalamic networks and hippocampal dysfunctions produce deficits in multiple behavioral domains. These changes that have been confirmed by multistructural neuroimaging studies are due to a causal cascade linking molecular pathologies (glutamate-mediated excitotoxicity, mitochondrial dysfunctions inducing multiple biochemical and structural alterations) and deficits in multiple behavioral domains. The disruption of large-scale connectivities may explain the variability of behavior profiles and is useful in understanding the biological backgrounds of functional decline in HD. Such findings offer new avenues for targeted treatments in terms of minimizing neurobehavioral impairment in HD.
Keywords: Apathy; Behavioral changes; Disinhibition; Functional connectivity; Huntington disease; Irritability; Mitochondrial dysfunction.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Similar articles
-
AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.Clin Gastroenterol Hepatol. 2025 Jul;23(8):1291-1302. doi: 10.1016/j.cgh.2025.02.015. Epub 2025 May 19. Clin Gastroenterol Hepatol. 2025. PMID: 40387691 Review.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
-
Behavioural and cognitive behavioural therapy for obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD).Cochrane Database Syst Rev. 2021 Sep 3;9(9):CD013173. doi: 10.1002/14651858.CD013173.pub2. Cochrane Database Syst Rev. 2021. PMID: 34693989 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
Cited by
-
Molecular mechanisms and biomarkers in neurodegenerative disorders: a comprehensive review.Mol Biol Rep. 2025 Mar 26;52(1):337. doi: 10.1007/s11033-025-10463-w. Mol Biol Rep. 2025. PMID: 40138119 Review.
-
Behavioral disorders in multiple sclerosis: a comprehensive review.J Neural Transm (Vienna). 2025 Jan;132(1):1-22. doi: 10.1007/s00702-024-02816-9. Epub 2024 Sep 4. J Neural Transm (Vienna). 2025. PMID: 39231817 Review.
-
Neural Correlates of Huntington's Disease Based on Electroencephalography (EEG): A Mechanistic Review and Discussion of Excitation and Inhibition (E/I) Imbalance.J Clin Med. 2025 Jul 15;14(14):5010. doi: 10.3390/jcm14145010. J Clin Med. 2025. PMID: 40725699 Free PMC article. Review.
-
Concomitant pathologies and their impact on Huntington's disease. A brief review of current evidence.J Neural Transm (Vienna). 2025 Jun 21. doi: 10.1007/s00702-025-02957-5. Online ahead of print. J Neural Transm (Vienna). 2025. PMID: 40542842 Review. No abstract available.
References
-
- Anderson KE, Marshall FJ (2005) Behavioral symptoms associated with Huntington’s disease. Adv Neurol 96:197–208 - PubMed
-
- Arnoux I, Willam M, Griesche N, Krummeich J, Watari H, Offermann N, Weber S, Narayan Dey P, Chen C, Monteiro O, Buettner S, Meyer K, Bano D, Radyushkin K, Langston R, Lambert JJ, Wanker E, Methner A, Krauss S, Schweiger S, Stroh A (2018) Metformin reverses early cortical network dysfunction and behavior changes in Huntington’s disease. Elife 7:e38744
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical